Westway Health

Westway Health is a biopharmaceutical company based in Galway, Ireland, focusing on the development of non-antibiotic antimicrobials. The company was founded in 2012 and has since made significant strides in addressing the issue of antimicrobial resistance. Led by Prof Vincent O’Flaherty and CEO Dr. Ruairi Friel, the research team has developed a range of non-antibiotic antimicrobial technologies effective against all microorganisms, including antibiotic-resistant organisms such as MRSA. The unique mechanism of action of these technologies makes it highly improbable for microorganisms to develop a resistance, positioning Westway Health as a frontrunner in providing safe and effective solutions for future antimicrobial challenges. The company's flagship product, PanaMast, is currently being developed for commercialization under the H2020 SME Phase 2 instrument. With a focus on applications in human health, animal health, and environmental sterilization, Westway Health has attracted a €2.50M Venture Round investment in August 2017 to further its groundbreaking work.